An error was published in Table 2, row 5 of our manuscript in the July issue 2022 of Haematologica.1 The number for the Pacritinib group was erroneously published as 17.9 (5/28) and should be 25.0 (19/76). The corrected Table 2 is shown here.
Corrected Table 2.Spleen volume response and modified Total Symptom Score response rates among patients randomized to pacritinib versus best available therapy by subgroup: prior exposure to a JAK2 inhibitor (including ruxolitinib) and myelofibrosis subtype (primary vs. secondary after a prior diagnosis of polycythemia vera or essential thrombocythemia).
Footnotes
- Received December 5, 2023
- Accepted December 5, 2023
Correspondence
References
- Verstovsek S, Mesa R, Talpaz M. Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia. Haematologica. 2022; 107(7):1599-1607. https://doi.org/10.3324/haematol.2021.279415|PubMed|PubMed Central|Google Scholar
Figures & Tables
Corrected Table 2.Spleen volume response and modified Total Symptom Score response rates among patients randomized to pacritinib versus best available therapy by subgroup: prior exposure to a JAK2 inhibitor (including ruxolitinib) and myelofibrosis subtype (primary vs. secondary after a prior diagnosis of polycythemia vera or essential thrombocythemia).
Article Information
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.